Skip to Main Content
Contribute Try STAT+ Today

A drug from Amgen designed to block the cancer protein known as KRAS shrank tumors in 37% of patients with advanced lung cancer and delayed tumor progression by just under seven months, according to results from a clinical trial announced Thursday.

The Amgen drug, a pill called sotorasib, is the most important medicine in Amgen’s cancer research pipeline. It’s being tracked closely by researchers and investors because of its potential to attack certain cancer cells with a genetic mutation that was previously thought to be unreachable.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.